Article
Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug Development
2024-06-03
Abstract excerpt
The regulatory approvals of tumor agnostic therapies have led to reevaluation of the drug development process. Conventional models of drug development are histology-based. On the other hand, tumor agnostic drug development of a new drug (or combination) focuses on targeting a common genomic biomarker in multiple cancers, regardless of histology. Basket-like clinical trials with multiple cohorts allow clinicians to...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ab4e58e8-c961-5b0a-835a-a5e8870ec1c7
- DOI
- 10.20944/preprints202406.0122.v1